Hemophilia A Clinical Trials

57 recruitingLast updated: June 17, 2026

There are 57 actively recruiting hemophilia a clinical trials across 38 countries. Studies span Phase 3, Phase 4, Phase 1, Not Applicable, Phase 2, Early Phase 1. Top locations include Tianjin, Tianjin Municipality, China, Seattle, Washington, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Hemophilia A Trials at a Glance

57 actively recruiting trials for hemophilia a are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Phase 3 with 11 trials, with the heaviest enrollment activity in Tianjin, Seattle, and Beijing. Lead sponsors running hemophilia a studies include Institute of Hematology & Blood Diseases Hospital, China, Hoffmann-La Roche, and Pfizer.

Browse hemophilia a trials by phase

Treatments under study

About Hemophilia A Clinical Trials

Looking for clinical trials for Hemophilia A? There are currently 41 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hemophilia A trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hemophilia A clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 57 trials

Recruiting
Phase 1Phase 2

An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency

Hemophilia AHemophilia BFactor VII Deficiency
Shanghai RAAS Blood Products Co., Ltd.76 enrolled9 locationsNCT07644832
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

Hemophilia A
Hoffmann-La Roche360 enrolled8 locationsNCT07416604
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Hemophilia A
Hoffmann-La Roche126 enrolled2 locationsNCT07416526
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A
Hoffmann-La Roche60 enrolled14 locationsNCT05987449
Recruiting
Phase 1

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Severe Hemophilia A
Pfizer15 enrolled7 locationsNCT06703606
Recruiting
Phase 4

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Hemophilia A
Sanofi20 enrolled2 locationsNCT06145373
Recruiting
Phase 3

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Hemophilia AHemophilia B
Pfizer173 enrolled23 locationsNCT05568719
Recruiting
Phase 1Phase 2

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Hemophilia A
Hoffmann-La Roche5 enrolled2 locationsNCT07226206
Recruiting

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Acquired Hemophilia A
Takeda25 enrolled1 locationNCT06461533
Recruiting

A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea

Acquired Hemophilia A
Takeda9 enrolled4 locationsNCT06550882
Recruiting
Phase 1

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Hemophilia A
Swedish Orphan Biovitrum24 enrolled8 locationsNCT06579144
Recruiting
Phase 4

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Hemophilia A
Octapharma28 enrolled16 locationsNCT05936580
Recruiting
Phase 4

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Severe Hemophilia A
Octapharma28 enrolled18 locationsNCT05935358
Recruiting
Phase 3

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Hemophilia AHemophilia B
Pfizer100 enrolled34 locationsNCT05611801
Recruiting

Synovial Proliferation on Routine Ultrasound: Active or Inactive?

HaemophiliaHemophilia AHemophilia B
Van Creveldkliniek46 enrolled1 locationNCT06809972
Recruiting
Phase 3

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Hemophilia A
Emory University5 enrolled2 locationsNCT04563520
Recruiting
Phase 3

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B

Hemophilia A or B
Suzhou Alphamab Co., Ltd.70 enrolled1 locationNCT07545395
Recruiting
Phase 1

Lentiviral FVIII Gene Therapy

Hemophilia A
Shenzhen Geno-Immune Medical Institute10 enrolled1 locationNCT03217032
Recruiting

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Cystic FibrosisHuntington DiseaseSickle Cell Disease+12 more
Assistance Publique - Hôpitaux de Paris550 enrolled1 locationNCT06147414
Recruiting

ATHNdataset Registry

ThrombosisSickle Cell DiseaseHemophilia A+6 more
American Thrombosis and Hemostasis Network200,000 enrolled1 locationNCT06820515